Mirtazapina Tecnigen (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which raises norepinephrine levels, and antagonizes certain serotonin receptors (5‑HT2 and 5‑HT3). This dual action enhances both norepinephrine and serotonin neurotransmission, contributing to its antidepressant effect.

The appropriate dose of Mirtazapina Tecnogen is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. It often causes sedation and weight gain, which can be advantageous for patients with insomnia or low appetite, whereas other antidepressants may have different side‑effect profiles.

Mirtazapina Tecnogen should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually once daily in the evening, as directed by the prescribing clinician. Tablets should be swallowed whole with water and not chewed or crushed unless otherwise instructed.

Serious risks include the potential for suicidal thoughts or behavior, especially early in treatment, severe allergic reactions such as Stevens‑Johnson syndrome, agranulocytosis, and rare cases of hepatic dysfunction. Patients should be monitored closely for any concerning symptoms.

Mirtazapina Tecnogen is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently taking monoamine oxidase inhibitors. Caution is also advised for individuals with severe liver impairment or uncontrolled cardiovascular disease.